Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 3 , Pages 254-259, May 2008

Primary solitary fibrous tumor (SFT) in the retroperitoneum

  • Itsuhiro Takizawa, M.D.

      Affiliations

    • Department of Regenerative and Transplant Medicine, Division of Urology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
  • ,
  • Toshihiro Saito, M.D., Ph.D.

      Affiliations

    • Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan
  • ,
  • Yasuo Kitamura, M.D., Ph.D.

      Affiliations

    • Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan
  • ,
  • Kei Arai, M.D., Ph.D.

      Affiliations

    • Department of Regenerative and Transplant Medicine, Division of Urology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
  • ,
  • Makoto Kawaguchi, M.D., Ph.D.

      Affiliations

    • Department of Pathology, Niigata Rousai Hospital, Niigata, Japan
  • ,
  • Kota Takahashi, M.D., Ph.D.

      Affiliations

    • Department of Regenerative and Transplant Medicine, Division of Urology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
  • ,
  • Noboru Hara, M.D., Ph.D.

      Affiliations

    • Department of Regenerative and Transplant Medicine, Division of Urology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
    • Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-25-227-2287; fax: +81-25-227-0784.

Received 29 January 2007; received in revised form 19 March 2007; accepted 20 March 2007. published online 10 December 2007.

Abstract 

Background

Solitary fibrous tumor (SFT) is an infrequent but distinct neoplasm, which generally arises from submesothelial connective tissue in the pleura. SFT is rarely recognized in extrathoracic sites, and histologically identical conditions have also been reported in the retroperitoneum, although their pathophysiology has not been extensively investigated.

Methods

We present four cases of primary SFT in the retroperitoneum, and review 37 similar cases in the previous literature.

Results

About 40% of patients were asymptomatic, and 19.2% and 15.4% presented with an abdominal mass and urinary symptoms, respectively. The tumor size ranged between 2 and 26 (mean 9.1) cm. Sixty-three percent of tumors showed nonspecific development with haphazard distribution of bland short spindle or polygonal cells with or without collagenous bundles and stromal hyalinization. In 22.0%, hemangiopericytomatous appearance was seen. About 15% of cases showed histologically malignant characteristics. The tumor cells were immunoreactive for vimentin in all cases, CD34 in 91% and Bcl-2 in 86%. All tumors were excised, and in 85.4% of cases, tumors did not recur postoperatively for 6 to 48 months. No significant difference was found between the recurrence rate of histologically benign and malignant cases. Cases positive for both CD34 and Bcl-2 had no recurrence.

Conclusions

The identification of SFT in the retroperitoneum is of importance because histopathological indicators of malignancy are not necessarily associated with clinical malignant potential in many cases of retroperitoneal SFT. Retroperitoneal SFT showing typical pathological features with expression of CD34 and Bcl-2 is associated with a favorable outcome following excision.

Keywords: Solitary fibrous tumor, Retroperitoneum, CD34, Bcl-2

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1078-1439(07)00087-7

doi:10.1016/j.urolonc.2007.03.024

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 3 , Pages 254-259, May 2008